Ezrin has been found to be over-expressed in invasive epithelial neoplasia, such as in estrogen-sensitive endometrial [25] and breast carcinomas [13], [27], and in highly aggressive sarcomas as well [11], [12], being related in many of these studies to the presence of tumor metastasis. This evidence concerns the gene EZR and breast carcinoma.